Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Insights and Forecast to 2028

Report ID: 1639737 | Published Date: Jan 2025 | No. of Page: 112 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Eculizumab
        1.2.3 Methylprednisolone
        1.2.4 Azathioprine
        1.2.5 Mycophenolate Mofetil
        1.2.6 Rituximab
    1.3 Market by Application
        1.3.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospitals
        1.3.3 Clinic
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2017-2028)
    2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Region
        2.2.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Region (2017-2022)
        2.2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Region (2023-2028)
    2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Dynamics
        2.3.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Industry Trends
        2.3.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
        2.3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges
        2.3.4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue
        3.1.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue (2017-2022)
        3.1.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2017-2022)
    3.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue
    3.4 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio
        3.4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2021
    3.5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players Head office and Area Served
    3.6 Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
    3.7 Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Type
    4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2017-2022)
    4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2023-2028)
5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application
    5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Application (2017-2022)
    5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2017-2028)
    6.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
        6.2.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2017-2022)
        6.2.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2023-2028)
        6.2.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2017-2028)
    6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
        6.3.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2017-2022)
        6.3.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2023-2028)
        6.3.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2017-2028)
    6.4 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
        6.4.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2017-2022)
        6.4.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2017-2028)
    7.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
        7.2.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2017-2022)
        7.2.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2023-2028)
        7.2.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2017-2028)
    7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
        7.3.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2017-2022)
        7.3.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2023-2028)
        7.3.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2017-2028)
    7.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
        7.4.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2017-2022)
        7.4.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2017-2028)
    8.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
        8.2.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2017-2028)
    8.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
        8.3.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2017-2028)
    8.4 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region
        8.4.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2017-2028)
    9.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
        9.2.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2017-2022)
        9.2.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2023-2028)
        9.2.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2017-2028)
    9.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
        9.3.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2017-2022)
        9.3.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2023-2028)
        9.3.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2017-2028)
    9.4 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
        9.4.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2017-2022)
        9.4.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2017-2028)
    10.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
        10.2.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2017-2028)
    10.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
        10.3.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2017-2028)
    10.4 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
        10.4.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Alexion Pharmaceuticals, Inc.
        11.1.1 Alexion Pharmaceuticals, Inc. Company Details
        11.1.2 Alexion Pharmaceuticals, Inc. Business Overview
        11.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.1.5 Alexion Pharmaceuticals, Inc. Recent Developments
    11.2 Teva Pharmaceuticals
        11.2.1 Teva Pharmaceuticals Company Details
        11.2.2 Teva Pharmaceuticals Business Overview
        11.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.2.4 Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.2.5 Teva Pharmaceuticals Recent Developments
    11.3 Fresenius Kabi AG
        11.3.1 Fresenius Kabi AG Company Details
        11.3.2 Fresenius Kabi AG Business Overview
        11.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.3.4 Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.3.5 Fresenius Kabi AG Recent Developments
    11.4 Pharmacia & Upjohn (a subsidary of Pfizer)
        11.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
        11.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
        11.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Developments
    11.5 Lupin Ltd.
        11.5.1 Lupin Ltd. Company Details
        11.5.2 Lupin Ltd. Business Overview
        11.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.5.4 Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.5.5 Lupin Ltd. Recent Developments
    11.6 Sagent Pharmaceuticals, Inc.
        11.6.1 Sagent Pharmaceuticals, Inc. Company Details
        11.6.2 Sagent Pharmaceuticals, Inc. Business Overview
        11.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.6.5 Sagent Pharmaceuticals, Inc. Recent Developments
    11.7 Zydus Pharmaceuticals, Inc.
        11.7.1 Zydus Pharmaceuticals, Inc. Company Details
        11.7.2 Zydus Pharmaceuticals, Inc. Business Overview
        11.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.7.5 Zydus Pharmaceuticals, Inc. Recent Developments
    11.8 Sandoz Inc. (Novartis)
        11.8.1 Sandoz Inc. (Novartis) Company Details
        11.8.2 Sandoz Inc. (Novartis) Business Overview
        11.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.8.4 Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.8.5 Sandoz Inc. (Novartis) Recent Developments
    11.9 Alkem Laboratories Ltd.
        11.9.1 Alkem Laboratories Ltd. Company Details
        11.9.2 Alkem Laboratories Ltd. Business Overview
        11.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.9.4 Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.9.5 Alkem Laboratories Ltd. Recent Developments
    11.10 Mylan Pharmaceuticals, Inc.
        11.10.1 Mylan Pharmaceuticals, Inc. Company Details
        11.10.2 Mylan Pharmaceuticals, Inc. Business Overview
        11.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.10.5 Mylan Pharmaceuticals, Inc. Recent Developments
    11.11 Hoffmann-La Roche/ Chugai Pharmaceutical
        11.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
        11.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
        11.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Developments
    11.12 MedImmune LLC
        11.12.1 MedImmune LLC Company Details
        11.12.2 MedImmune LLC Business Overview
        11.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.12.4 MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.12.5 MedImmune LLC Recent Developments
    11.13 RemeGen, Ltd.
        11.13.1 RemeGen, Ltd. Company Details
        11.13.2 RemeGen, Ltd. Business Overview
        11.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
        11.13.4 RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
        11.13.5 RemeGen, Ltd. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer

List of Tables
    Table 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Eculizumab
    Table 3. Key Players of Methylprednisolone
    Table 4. Key Players of Azathioprine
    Table 5. Key Players of Mycophenolate Mofetil
    Table 6. Key Players of Rituximab
    Table 7. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 8. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2017-2022)
    Table 11. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2023-2028)
    Table 13. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Trends
    Table 14. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
    Table 15. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges
    Table 16. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints
    Table 17. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Players (2017-2022)
    Table 19. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2021)
    Table 20. Ranking of Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
    Table 24. Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 27. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2017-2022)
    Table 28. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 29. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2023-2028)
    Table 30. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 31. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Application (2017-2022)
    Table 32. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 33. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Application (2023-2028)
    Table 34. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 35. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 36. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 37. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 38. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 39. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 41. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 42. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 43. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 44. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 45. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2023-2028) & (US$ Million)
    Table 52. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 53. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 54. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 55. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 56. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 57. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 64. Alexion Pharmaceuticals, Inc. Company Details
    Table 65. Alexion Pharmaceuticals, Inc. Business Overview
    Table 66. Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 67. Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 68. Alexion Pharmaceuticals, Inc. Recent Developments
    Table 69. Teva Pharmaceuticals Company Details
    Table 70. Teva Pharmaceuticals Business Overview
    Table 71. Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 72. Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 73. Teva Pharmaceuticals Recent Developments
    Table 74. Fresenius Kabi AG Company Details
    Table 75. Fresenius Kabi AG Business Overview
    Table 76. Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 77. Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 78. Fresenius Kabi AG Recent Developments
    Table 79. Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
    Table 80. Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
    Table 81. Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 82. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 83. Pharmacia & Upjohn (a subsidary of Pfizer) Recent Developments
    Table 84. Lupin Ltd. Company Details
    Table 85. Lupin Ltd. Business Overview
    Table 86. Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 87. Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 88. Lupin Ltd. Recent Developments
    Table 89. Sagent Pharmaceuticals, Inc. Company Details
    Table 90. Sagent Pharmaceuticals, Inc. Business Overview
    Table 91. Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 92. Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 93. Sagent Pharmaceuticals, Inc. Recent Developments
    Table 94. Zydus Pharmaceuticals, Inc. Company Details
    Table 95. Zydus Pharmaceuticals, Inc. Business Overview
    Table 96. Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 97. Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 98. Zydus Pharmaceuticals, Inc. Recent Developments
    Table 99. Sandoz Inc. (Novartis) Company Details
    Table 100. Sandoz Inc. (Novartis) Business Overview
    Table 101. Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 102. Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 103. Sandoz Inc. (Novartis) Recent Developments
    Table 104. Alkem Laboratories Ltd. Company Details
    Table 105. Alkem Laboratories Ltd. Business Overview
    Table 106. Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 107. Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 108. Alkem Laboratories Ltd. Recent Developments
    Table 109. Mylan Pharmaceuticals, Inc. Company Details
    Table 110. Mylan Pharmaceuticals, Inc. Business Overview
    Table 111. Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 112. Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 113. Mylan Pharmaceuticals, Inc. Recent Developments
    Table 114. Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
    Table 115. Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
    Table 116. Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 117. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 118. Hoffmann-La Roche/ Chugai Pharmaceutical Recent Developments
    Table 119. MedImmune LLC Company Details
    Table 120. MedImmune LLC Business Overview
    Table 121. MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 122. MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 123. MedImmune LLC Recent Developments
    Table 124. RemeGen, Ltd. Company Details
    Table 125. RemeGen, Ltd. Business Overview
    Table 126. RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
    Table 127. RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022) & (US$ Million)
    Table 128. RemeGen, Ltd. Recent Developments
    Table 129. Research Programs/Design for This Report
    Table 130. Key Data Information from Secondary Sources
    Table 131. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type: 2021 VS 2028
    Figure 2. Eculizumab Features
    Figure 3. Methylprednisolone Features
    Figure 4. Azathioprine Features
    Figure 5. Mycophenolate Mofetil Features
    Figure 6. Rituximab Features
    Figure 7. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2021 VS 2028
    Figure 8. Hospitals Case Studies
    Figure 9. Clinic Case Studies
    Figure 10. Others Case Studies
    Figure 11. Devic’s Syndrome (Neuromyelitis Optica) Treatment Report Years Considered
    Figure 12. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 13. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region: 2021 VS 2028
    Figure 15. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Players in 2021
    Figure 16. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2021)
    Figure 17. The Top 10 and 5 Players Market Share by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2021
    Figure 18. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 19. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Market Share by Type (2017-2028)
    Figure 20. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Market Share by Application (2017-2028)
    Figure 21. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Country (2017-2028)
    Figure 22. United States Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Canada Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 25. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Market Share by Type (2017-2028)
    Figure 26. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Market Share by Application (2017-2028)
    Figure 27. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Country (2017-2028)
    Figure 28. Germany Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. France Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. U.K. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Italy Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Russia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Nordic Countries Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 35. Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Market Share by Type (2017-2028)
    Figure 36. Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Market Share by Application (2017-2028)
    Figure 37. Asia Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Region (2017-2028)
    Figure 38. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. South Korea Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Australia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 44. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 45. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Market Share by Type (2017-2028)
    Figure 46. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Market Share by Application (2017-2028)
    Figure 47. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Country (2017-2028)
    Figure 48. Mexico Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. Brazil Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 50. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 51. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Market Share by Type (2017-2028)
    Figure 52. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Market Share by Application (2017-2028)
    Figure 53. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Country (2017-2028)
    Figure 54. Turkey Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. Saudi Arabia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. UAE Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 57. Alexion Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 58. Teva Pharmaceuticals Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 59. Fresenius Kabi AG Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 60. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 61. Lupin Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 62. Sagent Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 63. Zydus Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 64. Sandoz Inc. (Novartis) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 65. Alkem Laboratories Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 66. Mylan Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 67. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 68. MedImmune LLC Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 69. RemeGen, Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2017-2022)
    Figure 70. Bottom-up and Top-down Approaches for This Report
    Figure 71. Data Triangulation
    Figure 72. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Alexion Pharmaceuticals, Inc.
Teva Pharmaceuticals
Fresenius Kabi AG
Pharmacia & Upjohn (a subsidary of Pfizer)
Lupin Ltd.
Sagent Pharmaceuticals, Inc.
Zydus Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Alkem Laboratories Ltd.
Mylan Pharmaceuticals, Inc.
Hoffmann-La Roche/ Chugai Pharmaceutical
MedImmune LLC
RemeGen, Ltd.
Frequently Asked Questions
Devic’s Syndrome (Neuromyelitis Optica) Treatment report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Devic’s Syndrome (Neuromyelitis Optica) Treatment report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Devic’s Syndrome (Neuromyelitis Optica) Treatment report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Valet Robot

This report focuses on the global Valet Robot status, future forecast, growth opportunity, key ma ... Read More